Microwave ablation for papillary thyroid microcarcinoma monitored with contrast-enhanced ultrasound and genetic testing
Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study
This project will try microwave ablation guided by contrast-enhanced ultrasound and an 88-gene panel in adults with low-risk papillary thyroid microcarcinoma to see if it controls the tumor while preserving thyroid function.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 480 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT07054229 on ClinicalTrials.gov |
What this trial studies
This is a prospective observational study in which adults with a single low-risk papillary thyroid microcarcinoma (≤1 cm) who have undergone fine-needle aspiration and an 88-gene panel may choose microwave ablation or surgical resection. Treatment effects and prognosis will be followed using contrast-enhanced ultrasound combined with molecular diagnostic data. The study will track local tumor control, complications, thyroid function, and lesion changes over time. Data will be collected at Sun Yat-sen Memorial Hospital to compare outcomes and identify molecular markers linked to prognosis.
Who should consider this trial
Good fit: Adults aged 18–70 with a single low-risk papillary thyroid microcarcinoma ≤1 cm, no cervical lymph node or distant metastasis, no extrathyroidal extension, prior fine-needle aspiration and 88-gene panel testing, and who voluntarily choose microwave ablation or surgery are ideal candidates.
Not a fit: Patients with tumors in the thyroid isthmus, pathological high-risk subtypes, recent rapid tumor growth, pregnant or lactating women, or other exclusion criteria are unlikely to benefit from the microwave ablation approach studied here.
Why it matters
Potential benefit: If successful, microwave ablation could offer effective tumor control with fewer complications and better preservation of thyroid function than conventional surgery.
How similar studies have performed: Other observational studies have shown promising local control and safety for microwave ablation in low-risk PTMC, but combining contrast-enhanced ultrasound with an 88-gene molecular panel for prognosis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18-70 years, gender not specified; * Patients with low-risk PTMC receiving initial treatment (meeting all the following conditions: single lesion with a maximum diameter ≤1cm; no cervical lymph node metastasis; no distant metastasis; no extrathyroidal extension; no family history of thyroid cancer; no history of head and neck radiation during childhood); * Patients who have undergone fine-needle aspiration cytology examination of thyroid nodules and 88-gene panel testing for thyroid cancer before surgery; * Patients voluntarily choose to undergo microwave ablation therapy or surgical resection. Exclusion Criteria: * Tumor located in the isthmus of the thyroid; * Pathological high-risk subtypes (tall cell subtype, columnar cell subtype, diffuse sclerosing subtype, solid/insular subtype, oncocytic subtype); * Progressive enlargement of the cancer lesion in the short term (increase of more than 3mm within 6 months); * Pregnant women, lactating women; * Patients with severe coagulation disorders; * Patients with contralateral vocal cord dysfunction; * Patients with contraindications to ultrasound contrast agents; * Other conditions deemed ineligible for enrollment by the investigator.
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Ou, Dr.
- Email: ouqy5@mail.sysu.edu.cn
- Phone: 020-34071020
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.